Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Genetics Generation AdvancementROCO:4160 -1.20%70 PB Ratio is 1.83 as of Jul. 14, 2026, which is 13% below its 10-year median of 2.10. GuruFocus rates ROCO:4160 with a GF Score™ of 70/100 and a GF Value™ of NT$51.36 (Modestly Undervalued). The stock has 8 warning signs investors should review. Among 196 Medical Diagnostics & Research companies, Genetics Generation Advancement ranks better than 55.1% on this metric.
Genetics Generation Advancement Corp stock PB Ratio (=1.85) is close to 5-year low of 1.71.
The historical rank and industry rank for Genetics Generation Advancement's PB Ratio or its related term are showing as below:
ROCO:4160'
s PB Ratio Range Over the Past 10 Years
Min: 1.5 Med: 2.1 Max: 6.64
Current: 1.83
During the past 13 years, Genetics Generation Advancement's highest PB Ratio was 6.64. The lowest was 1.50. And the median was 2.10.
ROCO:4160's PB Ratio is ranked better than 55.1% of 196
companies
in the Medical Diagnostics & Research industry
Industry Median: 1.99
vs ROCO:4160: 1.83
During the past 12 months, Genetics Generation Advancement's average Book Value Per Share Growth Rate was 8.80% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 20.10% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 15.80% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was 6.30% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Genetics Generation Advancement was 20.10% per year. The lowest was -7.90% per year. And the median was 0.65% per year.
Back to Basics: PB Ratio
Genetics Generation Advancement (ROCO:4160) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Genetics Generation Advancement PB Ratio Related Terms
Genetics Generation Advancement PB Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Genetics Generation Advancement's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Genetics Generation Advancement PB Ratio vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Genetics Generation Advancement's PB Ratio distribution charts can be found below:
* The bar in red indicates where Genetics Generation Advancement's PB Ratio falls into.
Genetics Generation Advancement PB Ratio Calculation
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Genetics Generation Advancement (ROCO:4160) has a PB Ratio of 1.83 as of Jul. 14, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Genetics Generation Advancement and its competitors. This is 13% below median its historical median of 2.10. Over the past decade, Genetics Generation Advancement's PB Ratio has ranged from 1.50 to 6.64. According to the industry distribution chart, Genetics Generation Advancement ranks #88 out of 196 companies in the Medical Diagnostics & Research industry, placing it in the top 44.9%.
Is Genetics Generation Advancement's PB Ratio too high?
Genetics Generation Advancement's current PB Ratio of 1.83 is 13% below median its 10-year median of 2.10. Over the past 10 years, this metric has ranged from a low of 1.50 to a high of 6.64. The Medical Diagnostics & Research industry median PB Ratio is 1.99. Genetics Generation Advancement's value of 1.83 is 8% below this industry median. Based on the distribution chart, Genetics Generation Advancement ranks #88 out of 196 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, Genetics Generation Advancement has a GF Score™ of 70/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Genetics Generation Advancement's PB Ratio compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Genetics Generation Advancement ranks #88 out of 196 companies for PB Ratio. This puts Genetics Generation Advancement in the upper half of its industry. The industry median PB Ratio is 1.99. Genetics Generation Advancement's value of 1.83 is 8% below this benchmark. Historically, Genetics Generation Advancement's own PB Ratio has ranged from 1.50 to 6.64 over the past decade. While the company's 10-year median is 2.10 vs. the industry median of 1.99, Genetics Generation Advancement has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Medical Diagnostics & Research company?
The median PB Ratio among Medical Diagnostics & Research companies is 1.99, based on 196 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Genetics Generation Advancement's current PB Ratio of 1.83 is 8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Genetics Generation Advancement and its competitors. For the Medical Diagnostics & Research industry, the median PB Ratio is 1.99 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Genetics Generation Advancement's current PB Ratio is 1.83, which is 13% below median its own 10-year median of 2.10. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genetics Generation Advancement stock overvalued right now?
Based on GuruFocus' analysis, Genetics Generation Advancement (ROCO:4160) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$51.36, compared to a current price of NT$41.15 — trading 19.9% below its estimated fair value. The current PB Ratio is 1.83, which is 13% below median its 10-year median of 2.10 and 8% below the Medical Diagnostics & Research industry median of 1.99. Genetics Generation Advancement's overall GF Score™ is 70/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Genetics Generation Advancement (ROCO:4160), the current PB Ratio is 1.83 as of Jul. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Genetics Generation Advancement (ROCO:4160) Overvalued in 2026?
Based on GuruFocus' analysis, Genetics Generation Advancement stock appears to be undervalued.
The current stock price of NT$41.15 is trading 19.9% below its estimated GF Value™ of NT$51.36.
GuruFocus considers Genetics Generation Advancement to be Modestly Undervalued.
Key valuation signals for ROCO:4160:
PB Ratio: 1.83 (13% below median its 10-year median of 2.10)
GF Value™: NT$51.36 vs. price of NT$41.15 (19.9% below fair value)
Industry Position: 8% below the Medical Diagnostics & Research median (#88 of 196)
No single metric tells the full story. See the ROCO:4160 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Genetics Generation Advancement Business Description
Genetics Generation Advancement Corp is a Taiwan based company specialized in genetic testing and scientific information. It is engaged in providing services for the detection of genetic defects and prevention in newborns. Their main services include amniotic fluid chromosome chip screening, pre-implantation genetic diagnosis, and Molecular DNA testing diagnostics. The company is focused on the majority of areas of maternal precision medicine, pediatric disease diagnosis, drug-associated diagnosis, non-invasive cancer detection, and precise health management. The business units of the company are the Genetic Testing Unit and Informatics business unit.
70GF Score
Get the complete analysis for ROCO:4160
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:4160 has been successfully added to your 
